Area of research
Physiology · Psychiatry and Mental health
Research interest
Research focused on Disease and Placebo, with related work in Alzheimer's disease, Dementia, Clinical trial. Notable publications include 'NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease', 'Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup', and 'Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease'.
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup
Revised criteria for the diagnosis and staging of Alzheimer’s disease
Pepinemab antibody blockade of SEMA4D in early Huntington’s disease: a randomized, placebo-controlled, phase 2 trial
Association of Factors With Elevated Amyloid Burden in Clinically Normal Older Individuals
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease
The National Institute on Aging and the Alzheimer's Association Research Framework for Alzheimer's disease: Perspectives from the Research Roundtable
Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer’s Disease
Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS)
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Amyloid‐ß‐directed immunotherapy for Alzheimer's disease
Cognitive and Functional Decline and Their Relationship in Patients with Mild Alzheimer's Dementia
A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
Designing drug trials for Alzheimer's disease: What we have learned from the release of the phase III antibody trials: A report from the EU/US/CTAD Task Force
Safety and biomarker effects of solanezumab in patients with Alzheimer's disease